GeneDx

Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, driven by a 17% YoY surge in high-value exome and genome revenue. Revenue of $114.4M exceeded the $111.0M mean estimate, while adjusted net income turned positive at $0.4M, significantly outperforming the projected $5.6M loss. Management reaffirmed FY26 revenue guidance of $475M–$490M and provided strong Q3 guidance of $122M–$124M, signaling continued momentum in clinical genomic adoption.